A PROOF-OF-PRINCIPLE HISTONE DEACETYLASE INHIBITOR TRIAL IN RESECTABLE AERODIGESTIVE TRACT CANCER: INTRATUMORAL DRUG LEVELS AND BIOMARKER RESPONSES

被引：0
|
作者：
Dragnev, K. [1 ]
Beumer, J. H. [2 ]
Anyang, B. [2 ]
Ma, T. [3 ]
Galimberti, F. [3 ]
Erkmen, C. P. [1 ]
Nugent, W. [1 ]
Rigas, J. [1 ]
Abraham, K. [1 ]
Johnstone, D. [1 ]
Memoli, V. [1 ]
Dmitrovsky, E. [3 ]
机构：
[1] Norris Cotton Canc Ctr, Lebanon, NH USA
[2] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[3] Geisel Sch Med, Hanover, NH USA
来源：
ANNALS OF ONCOLOGY | 2013年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9 / 9
页数：1
相关论文
共 5 条
  • [1] Vorinostat (V) intratumoral levels and biomarker response in a window of opportunity trial in patients with resectable aerodigestive tract cancer.
    Dragnev, Konstantin H.
    Beumer, Jan Hendrik
    Anyang, Bean
    Ma, Tian
    Galimberti, Fabrizio
    Erkmen, Cherie Parungo
    Nugent, William
    Rigas, James R.
    Abraham, Kathryn
    Johnstone, David
    Memoli, Vincent
    Dmitrovsky, Ethan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Murine transgenic lung cancer models guide a proof of principle histone deacetylase inhibitor trial in lung cancer patients
    Ma, Tian
    Galimberti, Fabrizio
    Erkmen, Cherie P.
    Memoli, Vincent
    Nugent, William
    Rigas, James
    Johnstone, David
    Li, Hua
    DiRenzo, James
    Freemantle, Sarah
    Dragnev, Konstantin
    Dmitrovsky, Ethan
    CANCER RESEARCH, 2011, 71
  • [3] A proof-of-principle trial of bexarotene in patients (pts) with resectable non-small cell lung cancer (NSCLC).
    Rigas, JR
    Dragnev, KH
    Petty, WJ
    Nugent, WC
    Memoli, VA
    Black, CC
    Lewis, LD
    Loewen, G
    Negro-Vilar, A
    Dmitrovsky, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 654S - 654S
  • [4] Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Patients with Lung Cancer
    Ma, Tian
    Galimberti, Fabrizio
    Erkmen, Cherie P.
    Memoli, Vincent
    Chinyengetere, Fadzai
    Sempere, Lorenzo
    Beumer, Jan H.
    Anyang, Bean N.
    Nugent, William
    Johnstone, David
    Tsongalis, Gregory J.
    Kurie, Jonathan M.
    Li, Hua
    DiRenzo, James
    Guo, Yongli
    Freemantle, Sarah J.
    Dragnev, Konstantin H.
    Dmitrovsky, Ethan
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (08) : 1545 - 1555
  • [5] Valproic Acid Signature Trial (VAST): A proof-of-principle study correlating pharmacology, pathology, and advanced imaging with genomic prediction of drug sensitivity in breast cancer.
    Cohen, A. L.
    Schabel, M.
    Bild, A.
    Werner, T. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
1